Comparison of efficacy and safety between R-CHOP and CHOEP regimen on patients with diffuse large B cell lymphoma

Objective: To compare the effect,progression-free survival(PFS) and overall survival(OS) of rituximab combined with cyclophosphamide,hydrochloride,vincristine,prednisone chemotherapy(R-CHOP) and CHOP combined with VP-16 regimen(CHOEP) on patients with diffuse large B-cell lymphoma.Methods: A total of 73 patients with diffuse large B-cell lymphoma(DLBCL) were non-randomly divided into two groups: 39 patients were treated with R-CHOP regimen for 4-6 cycles,the others treated with CHOEP regimen for 4-6 cycles.Results: In R-CHOP groups,14 complete response(CR) and 12 partial response(PR) were observed,the total response rate(CR + PR) was 71.8%(28 /39).In CHOEP groups,12 complete response(CR) and 11 partial response(PR) were observed,the total response rate(CR + PR) was 67.6%(23 /34).The rate of CR + PR was higher in R-CHOP group than that in CHOP + E group(71.8% vs 67.6%),but no statistical difference was found between the two groups(P 0.05).Minewhile we found that the clinical stage,LDH levels,origin of B-cell(GCB or Non-GCB) and bulky disease could affect the therapeutic effect with univariate analysis(P 0.05).A median follow-up of 28-mouth of PFS and OS: R-CHOP group were(54.8 ± 5.2) % and(65.4 ± 5.7) %,CHOEP group were(47.6 ± 4.5) % and(53.3 ± 4.9) %,respectively.There were significant differences between PFS and OS in the two groups(P 0.05).Conclusion: The combination of rituximab to the CHOP regimen significantly prolongs PFS and OS in patients with diffuse large B-cell lymphoma without significant increase of toxicity.